Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Venous thromboembolism, that consists of the interrelated conditions deep-vein thrombosis
and pulmonary embolism, is an under-appreciated vascular disease. In Western regions …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

This position paper provides a comprehensive guide for optimal follow-up of patients with
acute pulmonary embolism (PE), covering multiple relevant aspects of patient counselling. It …

Background Hereditary and acquired thrombophilia are risk factors for venous
thromboembolism (VTE). Whether testing helps guide management decisions is …

Background: A small randomized controlled trial suggested that dabigatran may be as
effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to …

Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100
years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence …

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in patients with cancer. Arterial …

Background Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight
heparin for treating cancer-associated VTE. Research Question Is rivaroxaban as efficient …

Despite the enthusiasm surrounding novel targeted agents and immunotherapies,
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …